Oragenics (NYSE:OGEN) versus XOMA (NASDAQ:XOMA) Head-To-Head Comparison

XOMA (NASDAQ:XOMA – Get Free Report) and Oragenics (NYSE:OGEN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for XOMA and Oragenics, as provided by MarketBeat.

XOMA currently has a consensus price target of $81.50, indicating a potential upside of 223.80%. Given XOMA’s stronger consensus rating and higher possible upside, analysts plainly believe XOMA is more favorable than Oragenics.

Insider and Institutional Ownership

95.9% of XOMA shares are held by institutional investors. Comparatively, 18.7% of Oragenics shares are held by institutional investors. 7.2% of XOMA shares are held by company insiders. Comparatively, 10.1% of Oragenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

XOMA has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Profitability

This table compares XOMA and Oragenics’ net margins, return on equity and return on assets.

Valuation & Earnings

This table compares XOMA and Oragenics”s gross revenue, earnings per share (EPS) and valuation.

Oragenics has lower revenue, but higher earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.

Summary

XOMA beats Oragenics on 9 of the 14 factors compared between the two stocks.

About XOMA

(Get Free Report)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

About Oragenics

(Get Free Report)

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.